Castle Biosciences Inc (NASDAQ:CSTL) price on current trading day, fall -3.02% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $31.19.
A look at the stock’s price movement, the close in the last trading session was $32.16, moving within a range at $30.6 and $32.6. The beta value (5-Year monthly) was 0.985 while the PE ratio in trailing twelve months stood at 156.03. Turning to its 52-week performance, $35.84 and $16.97 were the 52-week high and 52-week low respectively. Overall, CSTL moved -4.50% over the past month.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Castle Biosciences Inc’s market cap currently stands at around $847.20 million, with investors looking forward to this quarter’s earnings report slated for in January.
Analysts have a consensus estimate of 80.58M for the company’s revenue for the quarter, with a low and high estimate of 75.4M and 84.49M respectively. The average forecast suggests up to a 21.86% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 326.31M, representing a 48.47% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CSTL is a 50% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend CSTL as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CSTL’s current price about 1.81% and 0.16% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 51.14, while 7-day volatility ratio is 5.47% and 5.18% in the 30-day chart. Further, Castle Biosciences Inc (CSTL) has a beta value of 0.89, and an average true range (ATR) of 1.64. Analysts have given the company’s stock an average 52-week price target of $40.5, forecast between a low of $36 and high of $45. Looking at the price targets, the low is -15.42% off current price level while to achieve the yearly target high, price needs to move -44.28%. Nonetheless, investors will most likely welcome a -29.85% jump to $40.5 which is the analysts’ median price.
If we refocus on Castle Biosciences Inc (NASDAQ:CSTL), historical trading data shows that trading volumes averaged 0.3 over the past 10 days and 386.42K over the past 3 months. The company’s latest data on shares outstanding shows there are 27.98 million shares.
The 3.08% of Castle Biosciences Inc’s shares are in the hands of company insiders while institutional holders own 92.08% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 1.71 million on 2024-11-15, giving us a short ratio of 3.63. The data shows that as of 2024-11-15 short interest in Castle Biosciences Inc (CSTL) stood at 629.0 of shares outstanding, with shares short falling to 1.75 million registered in 2024-10-15. Current price change has pushed the stock 44.53% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CSTL stock continues to rise going into the next quarter.
